News & Updates

Atopic dermatitis (AD) is a chronic relapsing skin disease that requires long-term control. At the 25th World Congress of Dermatology (WCD) in Singapore, Professor Sonja Ständer, professor of dermatology and neurodermatology at the University Hospital Münster, Germany, and Professor Zuotao Zhao, dermatologist from the First Hospital, Peking University, Beijing, China, shared clinical approaches to managing patients with moderate-to-severe AD. The session was chaired by Professor Johannes Ring, director, Department of Dermatology and Allergy, Biederstein at the Technical University of Munich, Germany. Among the key topics discussed were the multifactorial nature of AD, its primary symptoms, and the various therapeutic options for itch relief.

Treatment with oral Janus kinase (JAK) inhibitors or jakinibs appeared well tolerated in patients with atopic dermatitis  (AD) as shown in an Asian retrospective cohort study.

At an honorary degree conferment ceremony held at the Chinese University of Hong Kong and an interview with MIMS Doctor, Professor Katalin Karikó, a pioneer of mRNA technology, suggested that recent advances in mRNA research can provide a versatile tool for combating various diseases.

Topical diclofenac gel significantly reduced the incidence of hand-foot syndrome (HFS) in patients with gastrointestinal (GI) cancer receiving capecitabine, according to findings from the exploratory subgroup analysis of the D-ToRCH* trial.

Mohs micrographic surgery (MMS) as the surgical modality for primary cutaneous Merkel cell carcinoma (MCC) is not inferior to wide-local excision (WLE), showing no survival disadvantage, according to a recent study.

The monoclonal antibody dupilumab, alone or in combination with conventional agents, appeared to effectively control bullous pemphigoid (BP), a study from China has shown.

New drug applications approved by US FDA as of 16-31 July 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Treatment with JNJ-77242113, an oral interleukin-23 receptor (IL-23R) antagonist peptide, leads to significant improvement in skin lesions, as measured by the Psoriasis Area and Severity Index (PASI) scores, in patients with moderate-to-severe plaque psoriasis, according to the FRONTIER 1 study presented at WCD 2023.